CLINICAL_TRIALS trial_result · 2022-06-29

Clinical Trial Update: Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) [Phase 3]

Phase 3 trial updating safety and efficacy of PRX-102 in Fabry disease patients already treated with agalsidase alfa (REPLAGAL).

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Protalix | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2022-06-29